Maze Therapeutics (MAZE) News Today $11.39 +0.09 (+0.80%) As of 03:21 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Maze Therapeutics (NASDAQ:MAZE) Trading Up 6.4% - Should You Buy?Maze Therapeutics (NASDAQ:MAZE) Shares Up 6.4% - Here's What HappenedMarch 11 at 5:52 PM | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Shares Up 3.5% - Time to Buy?Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 3.5% - Here's WhyMarch 5, 2025 | marketbeat.comMaze Therapeutics, Inc.'s (NASDAQ:MAZE) Quiet Period Will Expire on March 12thMarch 5, 2025 | americanbankingnews.comMaze Therapeutics, Inc.'s (NASDAQ:MAZE) Quiet Period To End on March 12thMaze Therapeutics' (NASDAQ:MAZE - Get Free Report) quiet period is set to end on Wednesday, March 12th. Maze Therapeutics had issued 8,750,000 shares in its public offering on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. During Maze Therapeutics' quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.March 5, 2025 | marketbeat.comTD Cowen Upgrades Maze Therapeutics (NASDAQ:MAZE) to "Strong-Buy"TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday.February 27, 2025 | marketbeat.comFY2024 Earnings Estimate for MAZE Issued By Leerink PartnrsMaze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Research analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Maze Therapeutics in a research note issued on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz forecasts that the company will earnFebruary 27, 2025 | marketbeat.comMaze Therapeutics IncFebruary 27, 2025 | morningstar.comMaze Therapeutics receives positive ratings following recent IPOFebruary 26, 2025 | finance.yahoo.comMaze Therapeutics initiated with an Overweight at JPMorganFebruary 26, 2025 | markets.businessinsider.comMaze Therapeutics (NASDAQ:MAZE) Raised to Strong-Buy at Leerink PartnrsLeerink Partnrs upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday.February 26, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Trading Up 5.6% - Should You Buy?Maze Therapeutics (NASDAQ:MAZE) Trading 5.6% Higher - Here's WhyFebruary 25, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Earns Buy Rating from Analysts at GuggenheimGuggenheim started coverage on shares of Maze Therapeutics in a research note on Tuesday. They set a "buy" rating and a $19.00 target price for the company.February 25, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Coverage Initiated at JPMorgan Chase & Co.JPMorgan Chase & Co. assumed coverage on Maze Therapeutics in a research note on Tuesday. They issued an "overweight" rating and a $30.00 target price on the stock.February 25, 2025 | marketbeat.comLeerink Partners Initiates Coverage on Maze Therapeutics (NASDAQ:MAZE)Leerink Partners initiated coverage on shares of Maze Therapeutics in a research report on Tuesday. They issued an "outperform" rating and a $28.00 target price on the stock.February 25, 2025 | marketbeat.comMaze Therapeutics initiated with an Outperform at LeerinkFebruary 25, 2025 | markets.businessinsider.comMaze Therapeutics initiated with a Buy at TD CowenFebruary 25, 2025 | markets.businessinsider.comMaze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders MarketFebruary 25, 2025 | tipranks.comMaze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829February 25, 2025 | tipranks.comPromising Drug Candidates and Market Potential Drive Buy Rating for Maze TherapeuticsFebruary 25, 2025 | tipranks.comMaze Therapeutics (NASDAQ:MAZE) Sets New 1-Year Low - What's Next?Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month Low - Here's WhyFebruary 15, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Stock Price Down 3.9% - What's Next?Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 3.9% - Here's WhyFebruary 13, 2025 | marketbeat.comMaze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney DiseaseFebruary 7, 2025 | globenewswire.comMaze Therapeutics Seeks IPO For Trials Ramp-UpJanuary 13, 2025 | seekingalpha.com Remove Ads Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address MAZE Media Mentions By Week MAZE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MAZE News Sentiment▼0.470.71▲Average Medical News Sentiment MAZE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MAZE Articles This Week▼23▲MAZE Articles Average Week Remove Ads Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ImmunityBio News Today CG Oncology News Today Belite Bio News Today Agios Pharmaceuticals News Today Harmony Biosciences News Today Vera Therapeutics News Today Janux Therapeutics News Today Tarsus Pharmaceuticals News Today Galapagos News Today Arcutis Biotherapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MAZE) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
